Last reviewed · How we verify
Keverprazan
At a glance
| Generic name | Keverprazan |
|---|---|
| Also known as | Potassium-competitive acid blocker |
| Sponsor | Nanjing First Hospital, Nanjing Medical University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection (PHASE3)
- Acid-suppression Drugs After Prophylactic Endoscopic Variceal Treatment of Esophagogastric Variceal Bleeding in Cirrhosis (NA)
- Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment (PHASE4)
- Keverprazan Combined with Amoxicillin for the Treatment of Helicobacter Pylori (NA)
- The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication (EARLY_PHASE1)
- Comparison of Keverprazan Hydrochloride-Amoxicillin Dual Therapy and Susceptibility-Guided Quadruple Therapy for Helicobacter Pylori Rescue Treatment (PHASE3)
- Optimization of Keverprazan-amoxicilli Dual Therapy for Helicobacter Pylori (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Keverprazan CI brief — competitive landscape report
- Keverprazan updates RSS · CI watch RSS
- Nanjing First Hospital, Nanjing Medical University portfolio CI